Please login to the form below

Not currently logged in
Email:
Password:

value-based pricing

This page shows the latest value-based pricing news and features for those working in and with pharma, biotech and healthcare.

Making a list and checking it twice…

Making a list and checking it twice…

And about making it more difficult to distribute fentanyl and oxycodone-based drugs. ... How long have we heard about value-based pricing and risk-sharing as possible panaceas to the unsustainability of health system costs?

Latest news

  • UK government tables bill on medicine pricing reforms UK government tables bill on medicine pricing reforms

    UK government tables bill on medicine pricing reforms. New scheme proposes single payment mechanism for old and new drugs alike. ... The proposed system would appear to draw a line under the UK's flirtation with the concept of value-based pricing as a

  • European pharma considering medicine pricing shakeup European pharma considering medicine pricing shakeup

    European pharma considering medicine pricing shakeup. EFPIA will later this month discuss proposals for a value-based pricing system. ... In the future, we believe we can contribute to more sustainable healthcare systems by developing new pricing models,

  • Tension expected as cancer market rises to $150bn-plus Tension expected as cancer market rises to $150bn-plus

    Tension expected as cancer market rises to $150bn-plus. IMS Health report anticipates increased demand for value-based pricing of oncology drugs. ... Debate on cancer drug pricing is expected to feature prominently alongside clinical analyses once again

  • UK pharma's contribution to NHS hits £1bn mark UK pharma's contribution to NHS hits £1bn mark

    The AAR was announced by Minister for Life Sciences George Freeman in November 2014 after it became apparent that plans to replace the PPRS with a value-based pricing model - along

  • The Italian Job The Italian Job

    The Italian Job. Therapy efficacy and value-based reimbursement models. In my August column in this publication, I spoke about the need for establishing a mechanism that would allow stakeholders to ... Express Scripts will launch a new value-based

More from news
Approximately 13 fully matching, plus 113 partially matching documents found.

Latest Intelligence

  • Communicating with payers to improve patient access Communicating with payers to improve patient access

    Develop ICPs to benchmark health outcomes. A key part of patient-centricity is developing strategies that add value to the touchpoints of the patients' journeys. ... Utilise real-world data to demonstrate outcomes. With payers increasingly imposing

  • Digital Business Models Digital Business Models

    Cloud-based real-world big data and real-time patient monitoring will drive value analytics, providing insights into patient outcomes that will drive successful value-based pricing. ... The life sciences industry should establish a data supply chain that

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    of a new drug pricing system, known as value-based pricing (VBP). ... Speaking to PME for its UK Pricing, Value and Access supplement, Burstow said: “ Really, we've gained no insight or learning from the dozens of drugs being funded within the scheme.

  • Communicating value Communicating value

    But what is value? And how can industry best demonstrate and communicate it? ... The failure to create the much-heralded value-based pricing system in the UK shows the limitations of HTA systems.

  • Value-based assessment Value-based assessment

    Value-based assessment. NICE is set to modify the way it operates, but the changes shouldn’ t come as a surprise. ... If you would like to know more about HTA or value based assessment please email rhowells@dresourcesgroup.com or visit.

More from intelligence
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Deal Tectonics: at the fault line of growth goals and competitive pressures

    The previous industry M&A record was set in 2014 exceeding US$200b in aggregate value. ... In 2016, a renewed focus on value-based drug pricing, staunch competition across key therapeutic battlegrounds and consolidated payer clout may exacerbate existing

  • EY Life Sciences

    The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. ... In 2016, a renewed focus on value-based drug pricing, staunch competition across key therapeutic battlegrounds and consolidated payer clout may

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics